
Thomas N Denny

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5919940/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials. Translational Research, 2022, 242, 38-55.	5.0	41
2	Age-Related Changes in the Nasopharyngeal Microbiome Are Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Symptoms Among Children, Adolescents, and Young Adults. Clinical Infectious Diseases, 2022, 75, e928-e937.	5.8	22
3	Severe Acute Respiratory Syndrome Coronavirus 2 Infections Among Children in the Biospecimens from Respiratory Virus-Exposed Kids (BRAVE Kids) Study. Clinical Infectious Diseases, 2021, 73, e2875-e2882.	5.8	51
4	Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature, 2021, 594, 553-559.	27.8	199
5	New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention, and Cure. Journal of Virology, 2021, 95, .	3.4	21
6	Mucosal-associated invariant TÂcell responses differ by sex in COVID-19. Med, 2021, 2, 755-772.e5.	4.4	24
7	InÂvitro and inÂvivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell, 2021, 184, 4203-4219.e32.	28.9	228
8	Streamlined Subpopulation, Subtype, and Recombination Analysis of HIV-1 Half-Genome Sequences Generated by High-Throughput Sequencing. MSphere, 2020, 5, .	2.9	1
9	Genetic variability of the U5 and downstream sequence of major HIV-1 subtypes and circulating recombinant forms. Scientific Reports, 2020, 10, 13214.	3.3	3
10	Redirection of Cord Blood T Cells and Natural Killer Cells for Elimination of Autologous HIV-1-Infected Target Cells Using Bispecific DART® Molecules. Frontiers in Immunology, 2020, 11, 713.	4.8	10
11	Development of an international external quality assurance program for HIV-1 incidence using the Limiting Antigen Avidity assay. PLoS ONE, 2019, 14, e0222290.	2.5	9
12	Increased predominance of HIV-1 CRF01_AE and its recombinants in the Philippines. Journal of General Virology, 2019, 100, 511-522.	2.9	14
13	Application of area scaling analysis to identify natural killer cell and monocyte involvement in the GranToxiLux antibody dependent cellâ€mediated cytotoxicity assay. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2018, 93, 436-447.	1.5	18
14	Distinctive variation in the U3R region of the 5' Long Terminal Repeat from diverse HIV-1 strains. PLoS ONE, 2018, 13, e0195661.	2.5	9
15	Comparison of Detection Limits of Fourth- and Fifth-Generation Combination HIV Antigen-Antibody, p24 Antigen, and Viral Load Assays on Diverse HIV Isolates. Journal of Clinical Microbiology, 2018, 56, .	3.9	34
16	Multiplex assay reliability and long-term intra-individual variation of serologic inflammatory biomarkers. Cytokine, 2017, 90, 185-192.	3.2	48
17	Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzee. Retrovirology, 2017, 14, 35.	2.0	12
18	Computational analysis of antibody dynamics identifies recent HIV-1 infection. JCI Insight, 2017, 2, .	5.0	11

#	Article	IF	CITATIONS
19	Fast Dissemination of New HIV-1 CRF02/A1 Recombinants in Pakistan. PLoS ONE, 2016, 11, e0167839.	2.5	15
20	Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques. Molecular Therapy, 2016, 24, 2021-2032.	8.2	41
21	Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. EBioMedicine, 2016, 14, 97-111.	6.1	47
22	Variability of the IFN-Î ³ ELISpot assay in the context of proficiency testing and bridging studies. Journal of Immunological Methods, 2016, 433, 69-76.	1.4	6
23	Genetic Characterization of a Panel of Diverse HIV-1 Isolates at Seven International Sites. PLoS ONE, 2016, 11, e0157340.	2.5	13
24	Quality assurance for HIV point-of-care testing and treatment monitoring assays. African Journal of Laboratory Medicine, 2016, 5, 557.	0.6	8
25	A Brief Chronicle of CD4 as a Biomarker for HIV/AIDS: A Tribute to the Memory of John L. Fahey. Forum on Immunopathological Diseases and Therapeutics, 2015, 6, 57-65.	0.1	10
26	CD4 Enumeration Technologies: A Systematic Review of Test Performance for Determining Eligibility for Antiretroviral Therapy. PLoS ONE, 2015, 10, e0115019.	2.5	28
27	Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1. Journal of Virology, 2015, 89, 9952-9961.	3.4	55
28	Neutralization Properties of Simian Immunodeficiency Viruses Infecting Chimpanzees and Gorillas. MBio, 2015, 6, .	4.1	25
29	Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes. Virology, 2015, 475, 37-45.	2.4	25
30	Maternal HIV-1 envelope–specific antibody responses and reduced risk of perinatal transmission. Journal of Clinical Investigation, 2015, 125, 2702-2706.	8.2	68
31	Aggregate complexes of HIV-1 induced by multimeric antibodies. Retrovirology, 2014, 11, 78.	2.0	26
32	Reconstructing a B-Cell Clonal Lineage. II. Mutation, Selection, and Affinity Maturation. Frontiers in Immunology, 2014, 5, 170.	4.8	104
33	Postnatal Cytomegalovirus Exposure in Infants of Antiretroviral-Treated and Untreated HIV-Infected Mothers. Infectious Diseases in Obstetrics and Gynecology, 2014, 2014, 1-8.	1.5	17
34	Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials. Journal of Immunological Methods, 2014, 409, 107-116.	1.4	34
35	Development and implementation of a proficiency testing program for Luminex bead-based cytokine assays. Journal of Immunological Methods, 2014, 409, 62-71.	1.4	34
36	Statistical methods for the assessment of EQAPOL proficiency testing: ELISpot, Luminex, and Flow Cytometry. Journal of Immunological Methods, 2014, 409, 72-81.	1.4	16

#	Article	IF	CITATIONS
37	Implementation of Good Clinical Laboratory Practice (GCLP) guidelines within the External Quality Assurance Program Oversight Laboratory (EQAPOL). Journal of Immunological Methods, 2014, 409, 91-98.	1.4	26
38	Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature, 2014, 505, 502-508.	27.8	140
39	Toward development of a comprehensive external quality assurance program for polyfunctional intracellular cytokine staining assays. Journal of Immunological Methods, 2014, 409, 44-53.	1.4	13
40	Development of a contemporary globally diverse HIV viral panel by the EQAPOL program. Journal of Immunological Methods, 2014, 409, 117-130.	1.4	42
41	Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells. Journal of Immunological Methods, 2014, 409, 147-160.	1.4	39
42	The External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN-γ ELISpot) assay. Journal of Immunological Methods, 2014, 409, 31-43.	1.4	22
43	Setting objective thresholds for rare event detection in flow cytometry. Journal of Immunological Methods, 2014, 409, 54-61.	1.4	14
44	Introduction to a Special Issue of the Journal of Immunological Methods: Building Global Resource Programs to Support HIV/AIDS Clinical Trial Studies. Journal of Immunological Methods, 2014, 409, 1-5.	1.4	6
45	The Center for HIV/AIDS Vaccine Immunology (CHAVI) multi-site quality assurance program for cryopreserved Human Peripheral Blood Mononuclear Cells. Journal of Immunological Methods, 2014, 409, 21-30.	1.4	19
46	Leukopak PBMC sample processing for preparing quality control material to support proficiency testing programs. Journal of Immunological Methods, 2014, 409, 99-106.	1.4	24
47	Influence of HLA-C Expression Level on HIV Control. Science, 2013, 340, 87-91.	12.6	352
48	Infectious Virion Capture by HIV-1 gp120-Specific IgG from RV144 Vaccinees. Journal of Virology, 2013, 87, 7828-7836.	3.4	59
49	Lack of B Cell Dysfunction Is Associated with Functional, gp120-Dominant Antibody Responses in Breast Milk of Simian Immunodeficiency Virus-Infected African Green Monkeys. Journal of Virology, 2013, 87, 11121-11134.	3.4	13
50	Transient Compartmentalization of Simian Immunodeficiency Virus Variants in the Breast Milk of African Green Monkeys. Journal of Virology, 2013, 87, 11292-11299.	3.4	6
51	Concerning the article by de Carvalho Bittencourt et al.: Value of HIV patients with regular followâ€up as inâ€house internal controls of flow cytometry measurement of lymphocyte subsets. Cytometry Part B - Clinical Cytometry, 2013, 84, 327-328.	1.5	0
52	Phenotypic properties of transmitted founder HIV-1. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6626-6633.	7.1	379
53	Elucidation of Hepatitis C Virus Transmission and Early Diversification by Single Genome Sequencing. PLoS Pathogens, 2012, 8, e1002880.	4.7	74
54	Antiviral Inhibitory Capacity of CD8+ÂT cells Predicts the Rate of CD4+ÂT-Cell Decline in HIV-1 Infection. Journal of Infectious Diseases, 2012, 206, 552-561.	4.0	74

#	Article	IF	CITATIONS
55	Initial HIV-1 Antigen-Specific CD8 ⁺ T Cells in Acute HIV-1 Infection Inhibit Transmitted/Founder Virus Replication. Journal of Virology, 2012, 86, 6835-6846.	3.4	56
56	VERITAS?: A Time for VERIQASâ,,¢ and a new approach to training, education, and the quality assessment of CD4+ T lymphocyte counting (I). , 2012, 82B, 93-100.		5
57	Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. Journal of Experimental Medicine, 2011, 208, 2237-2249.	8.5	198
58	The Magnitude and Kinetics of the Mucosal HIV-Specific CD8+ T Lymphocyte Response and Virus RNA Load in Breast Milk. PLoS ONE, 2011, 6, e23735.	2.5	5
59	H3N2 Influenza Infection Elicits More Cross-Reactive and Less Clonally Expanded Anti-Hemagglutinin Antibodies Than Influenza Vaccination. PLoS ONE, 2011, 6, e25797.	2.5	158
60	Multiple HIV-1-specific IgG3 responses decline during acute HIV-1. Aids, 2011, 25, 2089-2097.	2.2	79
61	Flow cytometric methods for prenatal and neonatal diagnosis. Journal of Immunological Methods, 2011, 363, 198-209.	1.4	8
62	HIV-Specific Functional Antibody Responses in Breast Milk Mirror Those in Plasma and Are Primarily Mediated by IgG Antibodies. Journal of Virology, 2011, 85, 9555-9567.	3.4	86
63	Origin and Evolution of HIV-1 in Breast Milk Determined by Single-Genome Amplification and Sequencing. Journal of Virology, 2011, 85, 2751-2763.	3.4	57
64	Comparison of interlaboratory variation in absolute Tâ€cell counts by singleâ€platform and optimized dualâ€platform methods. Cytometry Part B - Clinical Cytometry, 2010, 78B, 194-200.	1.5	20
65	A model for harmonizing flow cytometry in clinical trials. Nature Immunology, 2010, 11, 975-978.	14.5	130
66	Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce β-chemokines. Journal of Experimental Medicine, 2010, 207, 763-776.	8.5	51
67	Phenotypic and Functional Profile of HIV-Inhibitory CD8 T Cells Elicited by Natural Infection and Heterologous Prime/Boost Vaccination. Journal of Virology, 2010, 84, 4998-5006.	3.4	110
68	Evaluation and Recommendations on Good Clinical Laboratory Practice Guidelines for Phase I–III Clinical Trials. PLoS Medicine, 2009, 6, e1000067.	8.4	48
69	High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. Journal of Virological Methods, 2009, 158, 171-179.	2.1	235
70	Evaluation of the Blood Stabilizers TransFix™ and Cyto-Chex [®] BCT for Low-Cost CD4 T-Cell Methodologies. Viral Immunology, 2009, 22, 329-332.	1.3	12
71	The Global Health and Diagnostic (Flow) Cytometry-Breakthroughs in HIV and Tuberculosis. Cytometry Part B - Clinical Cytometry, 2008, 74B, S4-S5.	1.5	2
72	A North American multilaboratory study of CD4 counts using flow cytometric panleukogating (PLG): A NIAID-DAIDS Immunology Quality Assessment Program Study. Cytometry Part B - Clinical Cytometry, 2008, 74B, S52-S64.	1.5	23

#	Article	IF	CITATIONS
73	CD4 immunophenotyping in HIV infection. Nature Reviews Microbiology, 2008, 6, S7-S15.	28.6	57
74	Induction of Plasma (TRAIL), TNFR-2, Fas Ligand, and Plasma Microparticles after Human Immunodeficiency Virus Type 1 (HIV-1) Transmission: Implications for HIV-1 Vaccine Design. Journal of Virology, 2008, 82, 7700-7710.	3.4	76
75	Tissue-Specific Genetic Control of Splicing: Implications for the Study of Complex Traits. PLoS Biology, 2008, 6, e1000001.	5.6	243
76	Quality Assurance Program for Peripheral Blood Mononuclear Cell Cryopreservation. Vaccine Journal, 2007, 14, 1242-1244.	3.1	24
77	Reducing the Dose of Smallpox Vaccine Reduces Vaccineâ€Associated Morbidity without Reducing Vaccination Success Rates or Immune Responses. Journal of Infectious Diseases, 2007, 195, 826-832.	4.0	17
78	Assessing immunophenotyping performance: Proficiency-validation for adopting improved flow cytometry methods. Cytometry Part B - Clinical Cytometry, 2007, 72B, 249-255.	1.5	36
79	Seroprevalence of Toxoplasma gondii in Pregnant Women and Cats in Grenada, West Indies. Journal of Parasitology, 2006, 92, 644-645.	0.7	36
80	HLAâ€A2–Restricted Human CD8+Cytotoxic T Lymphocyte Responses to a Novel Epitope in Vaccinia Virus That Is Conserved among Orthopox Viruses. Journal of Infectious Diseases, 2006, 194, 168-175.	4.0	22
81	Effect of Pregnancy and Human Immunodeficiency Virus Infection on Intracellular Interleukin-2 Production Patterns. Vaccine Journal, 2004, 11, 780-785.	2.6	4
82	IL-10 levels in Dengue patients: Some findings from the exceptional epidemiological conditions in Cuba. Journal of Medical Virology, 2004, 73, 230-234.	5.0	93
83	Paradoxical effects of a stress signal on pro- and anti-apoptotic machinery in HTLV-1 Tax expressing cells. Molecular and Cellular Biochemistry, 2003, 245, 99-113.	3.1	25
84	Depressed interleukin-12-producing activity by monocytes correlates with adverse clinical course and a shift toward Th2-type lymphocyte pattern in severely injured male trauma patients. Critical Care Medicine, 2003, 31, 1722-1729.	0.9	124
85	Correlates of Nontransmission in US Women at High Risk of Human Immunodeficiency Virus Type 1 Infection through Sexual Exposure. Journal of Infectious Diseases, 2002, 185, 428-438.	4.0	66
86	Comparison of Human Immunodeficiency Virus Antigens as Stimulants for Lymphocyte Proliferation Assays. Vaccine Journal, 2002, 9, 525-529.	3.1	2
87	Vasoactive intestinal peptide (VIP) inhibits the proliferation of bone marrow progenitors through the VPAC1 receptor. Experimental Hematology, 2002, 30, 1001-1009.	0.4	34
88	Decreased Interferon-α Production in HIV-Infected Patients Correlates with Numerical and Functional Deficiencies in Circulating Type 2 Dendritic Cell Precursors. Clinical Immunology, 2001, 101, 201-210.	3.2	230
89	Increased incidence of sepsis and altered monocyte functions in severely injured type Aâ^' glucose-6-phosphate dehydrogenase-deficient African American trauma patients. Critical Care Medicine, 2001, 29, 728-736.	0.9	89
90	Relationship between oxidative burst activity and CD11b expression in neutrophils and monocytes from healthy individuals: Effects of race and gender. Cytometry, 2001, 46, 243-246.	1.8	31

#	ARTICLE	IF	CITATIONS
91	The dynamics of bone marrow stromal cells in the proliferation of multipotent hematopoietic progenitors by substance P: an understanding of the effects of a neurotransmitter on the differentiating hematopoietic stem cell. Journal of Neuroimmunology, 2001, 121, 22-31.	2.3	45
92	Inhibition of Human Immunodeficiency Virus Type 1 Transcription by Chemical Cyclin-Dependent Kinase Inhibitors. Journal of Virology, 2001, 75, 7266-7279.	3.4	129
93	NF-κB as a Central Mediator in the Induction of TGF-β in Monocytes from Patients with Idiopathic Myelofibrosis: An Inflammatory Response Beyond the Realm of Homeostasis. Journal of Immunology, 2000, 165, 2271-2277.	0.8	119
94	Loss of G1/S Checkpoint in Human Immunodeficiency Virus Type 1-Infected Cells Is Associated with a Lack of Cyclin-Dependent Kinase Inhibitor p21/Waf1. Journal of Virology, 2000, 74, 5040-5052.	3.4	69
95	Overexpression of p21 waf1 in Human T-Cell Lymphotropic Virus Type 1-Infected Cells and Its Association with Cyclin A/cdk2. Journal of Virology, 2000, 74, 7270-7283.	3.4	77
96	HIV heterosexual transmission: A hypothesis about an additional potential determinant. International Journal of Infectious Diseases, 2000, 4, 110-116.	3.3	17
97	Overexpression of basic fibroblast growth factor (FGF–2) downregulates Bcl–2 and promotes apoptosis in MCF–7 human breast cancer cells. Breast Cancer Research and Treatment, 1999, 56, 151-165.	2.5	43
98	Partial Resistance to Infection by R5X4 Primary HIV Type 1 Isolates in an Exposed-Uninfected Individual Homozygous for CCR5 32-Base Pair Deletion. AIDS Research and Human Retroviruses, 1999, 15, 1201-1208.	1.1	6
99	Effect of human immunodeficiency virus infection on serum beta2-microglobulin levels in pregnant women. Obstetrics and Gynecology, 1999, 94, 537-542.	2.4	3
100	CD3+CD8+ cell levels as predictors of transmission in human immunodeficiency virus-infected couples: A report from the heterosexual HIV transmission study. International Journal of Infectious Diseases, 1998, 2, 186-192.	3.3	11
101	Herpes simplex type II and Mycoplasma genitalium as risk factors for heterosexual HIV transmission: Report from the heterosexual hiv transmission study. International Journal of Infectious Diseases, 1998, 3, 5-11.	3.3	59
102	Basic Fibroblast Growth Factor Downregulates Bcl-2 and Promotes Apoptosis in MCF-7 Human Breast Cancer Cells. Experimental Cell Research, 1998, 238, 177-187.	2.6	57
103	Behavioral and Demographic Risk Factors for Transmission of Human Immunodeficiency Virus Type 1 in Heterosexual Couples: Report from the Heterosexual HIV Transmission Study. Clinical Infectious Diseases, 1998, 26, 855-864.	5.8	41
104	Single-Blind, Placebo Phase-in Trial of Two Escalating Doses of Selegiline in the Chronic Fatigue Syndrome. Neuropsychobiology, 1998, 37, 150-154.	1.9	46
105	The effect of total lymphoid irradiation and low-dose steroids on T lymphocyte populations in multiple sclerosis: correlation with clinical and MRI status. Journal of the Neurological Sciences, 1997, 152, 182-192.	0.6	10
106	Effect of vasoactive intestinal peptide (VIP) on cytokine production and expression of VIP receptors in thymocyte subsets. Regulatory Peptides, 1997, 72, 41-54.	1.9	20
107	Lymphocyte shedding from genital tract of human immunodeficiency virus–infected women: Immunophenotypic and clinical correlates. American Journal of Obstetrics and Gynecology, 1997, 176, 158-165.	1.3	14
108	Lymphocyte immunoregulatory cells present in semen from human immunodeficiency virus		9

#	Article	IF	CITATIONS
109	Quantitative determination of surface antibody binding capacities of immune subsets present in peripheral blood of healthy adult donors. , 1996, 26, 265-274.		38
110	Ranitidine improves lymphocyte function after severe head injury. Critical Care Medicine, 1996, 24, 1787-1792.	0.9	11
111	Evaluation of T-lymphocyte subsets present in semen and peripheral blood of healthy donors: A report from the heterosexual transmission study. Cytometry, 1995, 20, 349-355.	1.8	18
112	Guideline for flow cytometric immunophenotyping: A report from the national institute of allergy and infectious diseases, division of AIDS. Cytometry, 1993, 14, 702-715.	1.8	196
113	Immunologic Targets of HIV Infection: T Cells. Annals of the New York Academy of Sciences, 1993, 693, 35-51.	3.8	24
114	Lymphocyte Subsets in Healthy Children During the First 5 Years of Life. JAMA - Journal of the American Medical Association, 1992, 267, 1484.	7.4	157
115	An expert system model for detection of lymphocyte subsets. , 1992, , .		5
116	Polyclonal polymorphic B-cell lymphoproliferative disorder with prominent pulmonary involvement in children with acquired immune deficiency syndrome. Cancer, 1987, 59, 1455-1462.	4.1	79